Oscotec(039200) said on the 14th that it posted 56.3 billion won in consolidation sales in the first half of this year. That was up 371% from the same period a year earlier. Operating profit swung to a surplus of 28.7 billion won. Research and development expenses were 15 billion won, up 21% from a year earlier.
A 20 billion won milestone (upfront/technology fee) and royalty from the new lung cancer drug Leclaza were reflected in the results. Leclaza was developed by Oscotec subsidiary Genosco. Leclaza was transferred to Janssen, a Johnson & Johnson subsidiary, in 2018 after going through Yuhan in 2015.
Leclaza won U.S. Food and Drug Administration (FDA) approval in 2024 for a combination regimen used with Johnson & Johnson's cancer drug Rybrevant. Oscotec and Genosco receive a portion of Leclaza sales revenue as royalties from Johnson & Johnson. The two companies each receive 20% of the royalties, and the remaining 60% goes to Yuhan.
In June, Oscotec transferred its autoimmune disease drug candidate seviodoplenib to Agios Pharmaceuticals and received a contract payment of about 34 billion won. An Oscotec official said, "Based on the funds secured, we will continue research on anticancer drug candidates that overcome resistance."